268 related articles for article (PubMed ID: 11240212)
21. Tryptophan metabolism in the central nervous system: medical implications.
Ruddick JP; Evans AK; Nutt DJ; Lightman SL; Rook GA; Lowry CA
Expert Rev Mol Med; 2006 Aug; 8(20):1-27. PubMed ID: 16942634
[TBL] [Abstract][Full Text] [Related]
22. Tryptophan, adenosine, neurodegeneration and neuroprotection.
Stone TW; Forrest CM; Mackay GM; Stoy N; Darlington LG
Metab Brain Dis; 2007 Dec; 22(3-4):337-52. PubMed ID: 17712616
[TBL] [Abstract][Full Text] [Related]
23. [Kynurenines in pathogenesis of endogenous psychiatric disorders].
Shilov IuE; Bezrukov MV
Vestn Ross Akad Med Nauk; 2013; (1):35-41. PubMed ID: 23805637
[TBL] [Abstract][Full Text] [Related]
24. Changing the face of kynurenines and neurotoxicity: therapeutic considerations.
Bohár Z; Toldi J; Fülöp F; Vécsei L
Int J Mol Sci; 2015 Apr; 16(5):9772-93. PubMed ID: 25938971
[TBL] [Abstract][Full Text] [Related]
25. The role of kynurenines in disorders of the central nervous system: possibilities for neuroprotection.
Vamos E; Pardutz A; Klivenyi P; Toldi J; Vecsei L
J Neurol Sci; 2009 Aug; 283(1-2):21-7. PubMed ID: 19268309
[TBL] [Abstract][Full Text] [Related]
26. [Kynurenine and its metabolites in nervous system diseases].
Vécsei L; Schwab F
Orv Hetil; 1992 Jul; 133(29):1803-7. PubMed ID: 1386152
[TBL] [Abstract][Full Text] [Related]
27. Kynurenines, neurodegeneration and Alzheimer's disease.
Kincses ZT; Toldi J; Vécsei L
J Cell Mol Med; 2010 Aug; 14(8):2045-54. PubMed ID: 20629991
[TBL] [Abstract][Full Text] [Related]
28. Calretinin and calbindin D-28k delay the onset of cell death after excitotoxic stimulation in transfected P19 cells.
D'Orlando C; Fellay B; Schwaller B; Salicio V; Bloc A; Gotzos V; Celio MR
Brain Res; 2001 Aug; 909(1-2):145-58. PubMed ID: 11478931
[TBL] [Abstract][Full Text] [Related]
29. Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection.
Stone TW
Trends Pharmacol Sci; 2000 Apr; 21(4):149-54. PubMed ID: 10740291
[TBL] [Abstract][Full Text] [Related]
30. [The receptors involved in the excitatory effects of kynurenines].
Lapin IP; Ryzhov IV
Farmakol Toksikol; 1989; 52(1):98-104. PubMed ID: 2540028
[TBL] [Abstract][Full Text] [Related]
31. Mitochondrial disturbances, excitotoxicity, neuroinflammation and kynurenines: novel therapeutic strategies for neurodegenerative disorders.
Zádori D; Klivényi P; Szalárdy L; Fülöp F; Toldi J; Vécsei L
J Neurol Sci; 2012 Nov; 322(1-2):187-91. PubMed ID: 22749004
[TBL] [Abstract][Full Text] [Related]
32. Neuropharmacology of quinolinic and kynurenic acids.
Stone TW
Pharmacol Rev; 1993 Sep; 45(3):309-79. PubMed ID: 8248282
[TBL] [Abstract][Full Text] [Related]
33. Serum kynurenic acid is reduced in affective psychosis.
Wurfel BE; Drevets WC; Bliss SA; McMillin JR; Suzuki H; Ford BN; Morris HM; Teague TK; Dantzer R; Savitz JB
Transl Psychiatry; 2017 May; 7(5):e1115. PubMed ID: 28463241
[TBL] [Abstract][Full Text] [Related]
34. A Review on the Role and Function of Cinnabarinic Acid, a "Forgotten" Metabolite of the Kynurenine Pathway.
Gawel K
Cells; 2024 Mar; 13(5):. PubMed ID: 38474418
[TBL] [Abstract][Full Text] [Related]
35. Kynurenines in neurodegenerative disorders: therapeutic consideration.
Klivényi P; Toldi J; Vécsei L
Adv Exp Med Biol; 2004; 541():169-83. PubMed ID: 14977214
[No Abstract] [Full Text] [Related]
36. Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders.
Sas K; Robotka H; Toldi J; Vécsei L
J Neurol Sci; 2007 Jun; 257(1-2):221-39. PubMed ID: 17462670
[TBL] [Abstract][Full Text] [Related]
37. [Comparative analysis of quinolinic acid and L-kynurenine action on the electrically controlled membrane ion channels of mollusk neurons].
Artem'ev IIu
Fiziol Zh SSSR Im I M Sechenova; 1990 Aug; 76(8):1017-22. PubMed ID: 2176995
[TBL] [Abstract][Full Text] [Related]
38. Cannabinoids: Glutamatergic Transmission and Kynurenines.
Colín-González AL; Aguilera G; Santamaría A
Adv Neurobiol; 2016; 12():173-98. PubMed ID: 27651254
[TBL] [Abstract][Full Text] [Related]
39. Kynurenic acid antagonists and kynurenine pathway inhibitors.
Stone TW
Expert Opin Investig Drugs; 2001 Apr; 10(4):633-45. PubMed ID: 11281814
[TBL] [Abstract][Full Text] [Related]
40. Kynurenine pathway metabolites in humans: disease and healthy States.
Chen Y; Guillemin GJ
Int J Tryptophan Res; 2009; 2():1-19. PubMed ID: 22084578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
